DECIDUOUS THERAPEUTICS
Deciduous Therapeutics is an aging therapeutics company developing a novel class of immune-modulatory therapies that clear senescent cells and promote a healthy lifespan. Deciduous is led by Anil Bhushan, a professor at UCSF, and Robin Mansukhani, a five-time biotech founder.
DECIDUOUS THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care
Founded:
2018-01-01
Address:
San Francisco, California, United States
Country:
United States
Total Employee:
1+
Status:
Active
Contact:
650-206-9082
Total Funding:
6.5 M USD
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
BOA Nutrition
BOA Nutrition is a nutraceutical company based in North Carolina.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Janus Health
Janus is leapfrogging the low-code, no-code solutions of today by developing a vertically integrated process improvement platform.
Wavely Diagnostics
Wavely Diagnostics is a digital diagnostics company developing smartphone-based apps to bring accurate, data-driven virtual pediatric care.
Current Employees Featured
Founder
Investors List
Presight Capital
Presight Capital investment in Seed Round - Deciduous Therapeutics
8VC
8VC investment in Seed Round - Deciduous Therapeutics
Longevity Vision Fund
Longevity Vision Fund investment in Seed Round - Deciduous Therapeutics
CRV
CRV investment in Seed Round - Deciduous Therapeutics
More informations about "Deciduous Therapeutics"
About Us - Deciduous Therapeutics Inc.
Robin Mansukhani is CEO and Co-Founder of Deciduous Therapeutics. Previously, he co-founded and served as President & CEO of Alzeca Biosciences, an Alzheimer’s/CNS …See details»
Deciduous Therapeutics - Crunchbase Company Profile …
Deciduous Therapeutics is an aging therapeutics company developing a novel class of immune-modulatory therapies that clear senescent cells and promote a healthy lifespan. Deciduous is led by Anil Bhushan, a professor at UCSF, and …See details»
Deciduous Therapeutics Company Profile 2024: …
Deciduous Therapeutics General Information Description. Developer of novel therapeutics designed for the treatment of age-related diseases. The company's novel molecules can activate a critical endogenous immune surveillance …See details»
Deciduous Therapeutics - LinkedIn
Deciduous Therapeutics | 2,741 followers on LinkedIn. Deciduous is developing a novel class of immune-modulatory therapies designed to promote a healthy lifespan. | Senescent cells, …See details»
Deciduous Therapeutics - Funding, Financials, Valuation & Investors
Deciduous Therapeutics is an aging therapeutics company developing a novel class of immune modulatory therapies. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ...See details»
Deciduous Therapeutics - Org Chart, Teams, Culture & Jobs - The …
View Deciduous Therapeutics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. ... Find executives, board …See details»
Deciduous Therapeutics - VentureRadar
Deciduous Therapeutics is a biotechnology firm specializing in the development of innovative treatments for age-related diseases. Their groundbreaking approach involves the discovery of …See details»
Deciduous Therapeutics, Inc. - Drug pipelines, Patents, Clinical …
Explore Deciduous Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 5 news, and 1 literature.See details»
Deciduous Therapeutics - VentureRadar
Deciduous Therapeutics is an aging therapeutics company developing a novel class of immune modulatory therapies to promote healthy lifespan. Senescent cells accumulate and play a …See details»
Deciduous Therapeutics - Updates, News, Events, Signals & Triggers
Aug 31, 2023 Deciduous Therapeutics is focused on developing immune modulatory therapies, specifically through the activation of invariant natural killer T (iNKT) cells. Their research …See details»
Restoring immune surveillance to tackle age-related diseases
Deciduous Therapeutics was founded when Regis Kelly, director of the California Institute for Quantitative Biosciences (QB3) at UCSF, introduced Bhushan to life sciences entrepreneur, …See details»
Deciduous Therapeutics | CipherBio
Explore Deciduous Therapeutics's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Deciduous Therapeutics senolytics - lifespan.io
Lifespan Research Institute is a 501(c)(3) non-profit organization dedicated to promoting increased healthy human lifespan through fiscally sponsoring longevity research projects, and …See details»
Deciduous Therapeutics - Contacts, Employees, Board Members, …
Organization. Deciduous Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. Contacts 6. …See details»
Deciduous Therapeutics - Nature
Deciduous Therapeutics, explained, “rather than target a non-specific anti-apoptotic pathway on senescent cells, Deciduous is focused on directly restoring the body’s natural immune …See details»
Harnessing the immune system to target cellular senescence
May 11, 2021 Californian start-up Deciduous Therapeutics has emerged from stealth mode following the publication of a new paper that reveals the science behind its approach to …See details»
Exploring the antioxidant and antimicrobial properties of five ...
2 days ago A. quanzensis is a deciduous tree that can grow to heights of 20–30 m. Its leaves are compound, with numerous elliptical leaflets. Its leaves are compound, with numerous …See details»
Seed Round - Deciduous Therapeutics - 2022-12-31 - Crunchbase
Dec 31, 2022 Deciduous Therapeutics raised $10000000 on 2022-12-31 in Seed Round. Cookie Settings | Do Not Sell or Share My Personal InfoSee details»
Deciduous Therapeutics | VentureRadar
Deciduous Therapeutics is a biotechnology firm specializing in the development of innovative treatments for age-related diseases. Their groundbreaking approach involves the discovery of …See details»
Mersana Therapeutics Announces Additional FDA Fast Track …
1 day ago Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ETCAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. …See details»